Skip to content

Study · Animal study (in vivo) · chicken and rat · 1997

5 results

Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995).

Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD

Clinical cancer research : an official journal of the American Association for Cancer Research1 Feb 1997Cited by 66 (Europe PMC)

PMID9815682 (opens in a new tab)PepBankPUB-09815682
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In chick membranes, octreotide reduced vascular network density by 35.7% versus controls at 50 microgram (P < 0.05).

    In plain wordsIn chick membranes, octreotide reduced blood vessel network density compared with controls.

    Peptide
    Octreotide
    Outcome
    DecreaseVascular network density
    Study

    chickenn: not reported in source

    Chick chorioallantoic membrane
    Comparator
    Controls
    Outcome group
    Angiogenesis · Cardiovascular
    Studied dose
    50 microgramAs given in this study (chicken).

    Source sentences

    Summary
    as well as the density of the vascular network of the chick chorioallantoic membrane (mean, -35.7% versus controls at 50 microgram; P < 0.05).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In chick membranes, octreotide significantly inhibited neovascularization induced by FGF-3-secreting human mammary cells.

    In plain wordsIn chick membranes, octreotide significantly inhibited new blood vessel growth induced by human mammary cells that secreted FGF-3.

    Peptide
    Octreotide
    Outcome
    DecreaseFGF-3-associated neovascularization
    Study

    chickenn: not reported in source

    Chick chorioallantoic membrane with MCF-10Aint-2 cells
    Outcome group
    Angiogenesis · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, octreotide significantly inhibited chick chorioallantoic membrane neovascularization by the human MCF-10Aint-2 mammary cells secreting the angiogenic protein FGF-3.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, topical octreotide reduced induced corneal neovascularization by 50.6% versus controls (P < 0.05).

    In plain wordsIn rats, topical octreotide reduced induced corneal blood vessel growth compared with controls.

    Peptide
    Octreotide
    Outcome
    DecreaseCorneal neovascularization
    Study

    ratn: not reported in source

    AgNO3/KNO3-induced corneal neovascularization
    Comparator
    Controls
    Outcome group
    Angiogenesis · Cardiovascular
    Studied dose
    10 microgram/day · topical · 6 daysAs given in this study (rat).

    Source sentences

    Summary
    Topical administration of octreotide 10 microgram/day for 6 days inhibited rat cornea neovascularization induced by AgNO3/KNO3 (mean, -50.6% versus controls; P < 0.05).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, octreotide reduced compound 48/80-induced mesenteric neovascularization by 45.6% versus controls (P < 0.05).

    In plain wordsIn rats, octreotide reduced induced mesenteric blood vessel growth compared with controls.

    Peptide
    Octreotide
    Outcome
    DecreaseMesenteric neovascularization after compound 48/80
    Study

    ratn: not reported in source

    Compound 48/80-induced mesenteric angiogenesis
    Comparator
    Controls
    Outcome group
    Angiogenesis · Cardiovascular
    Studied dose
    40 microgram/day · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Octreotide 40 microgram/day i.p was tested on angiogenesis in rat mesentery obtained by i.p. injections of compound 48/80, a mast cell degranulating agent, or conditioned medium from MCF-10Aint-2 cells and was able to reduce the extent of neovascularization (mean, -45.6 and -64.1%, respectively, ver…
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats, octreotide reduced conditioned-medium-induced mesenteric neovascularization by 64.1% versus controls (P < 0.05).

    In plain wordsIn rats, octreotide reduced blood vessel growth induced by conditioned medium compared with controls.

    Peptide
    Octreotide
    Outcome
    DecreaseMesenteric neovascularization after conditioned medium
    Study

    ratn: not reported in source

    MCF-10Aint-2 conditioned-medium-induced mesenteric angiogenesis
    Comparator
    Controls
    Outcome group
    Angiogenesis · Cardiovascular
    Studied dose
    40 microgram/day · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Octreotide 40 microgram/day i.p was tested on angiogenesis in rat mesentery obtained by i.p. injections of compound 48/80, a mast cell degranulating agent, or conditioned medium from MCF-10Aint-2 cells and was able to reduce the extent of neovascularization (mean, -45.6 and -64.1%, respectively, ver…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.